The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Amgen's Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51

Wednesday, January 23, 2013

Amgen's Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.5116:01 EST Wednesday, January 23, 2013Full Year 2012 GAAP EPS Were $5.52 2013 Total Revenues and Adjusted EPS Expected to be in the Range of $17.8-$18.2 Billion and $6.85-$7.15, RespectivelyTHOUSAND OAKS, Calif., Jan. 23, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2012. Key results include:For the full year, total revenues increased 11 percent to $17,265 million, with 9 percent product sales growth driven by strong performance across the portfolio. Adjusted EPS grew 22 percent to $6.51 due to 15 percent adjusted operating income growth and lower shares outstanding.  For the fourth quarter, total revenues increased 11 percent to $4,421 million, with product sales growing at the same rate. Adjusted EPS grew 16 percent to $1.40 due to 11 percent adjusted operating income growth and lower shares outstanding.  GAAP EPS were $1.01 in the fourth quarter compared to $1.08 a year ago, and were $5.52 for the full year compared to $4.04 in 2011. Full year 2011 was negatively impacted by a previously disclosed charge for a legal settlement reserve. Free cash flow for the full year was $5.2 billion compared to $4.5 billion in 2011. The Company announced that it has initiated Phase 3 studies for AMG 145 in subjects with high levels of low-density lipoprotein (LDL) cholesterol.  "We achieved strong operating performance in 2012 as we delivered for patients and created value for shareholders," said Robert A. Bradway, chairman and chief executive officer at Amgen.  "We enter 2013 with good momentum, a broad late-stage pipeline and a continued focus on building our business internationally."Year-over-YearYear-over-Year$Millions, except EPS and percentagesQ4 '12Q4 '11YOY ?FY '12FY '11YOY ?Total Revenues$4,421$3,97311%$17,265$15,58211%Adjusted Net Income1,0881,0395%5,1194,8585%Adjusted EPS1.401.2116%6.515.3322%GAAP Net Income788934(16%)4,3453,68318%GAAP EPS$1.01$1.08(6%)$5.52$4.0437%References in this release to "adjusted" measures, measures presented "on an adjusted basis" or to free cash flow refer to non-GAAP financial measures.  These adjustments and other items are presented on the attached reconciliations.  Product Sales PerformanceTotal product sales increased 9 percent for the full year, driven by strong performance across the portfolio.  Product sales increased 11 percent for the fourth quarter of 2012 versus the fourth quarter of 2011 driven by Enbrel® (etanercept), XGEVA® (denosumab) and Prolia® (denosumab). Combined Neulasta® (pegfilgrastim) and NEUPOGEN® (Filgrastim) sales declined 1 percent for the fourth quarter of 2012 versus the fourth quarter of 2011, and increased 3 percent for the full year. Global Neulasta sales for the fourth quarter of 2012 versus the fourth quarter of 2011 were flat as price increases were offset by unit declines and unfavorable inventory changes. Sales increased 4 percent for the full year mainly due to price increases. Global NEUPOGEN sales for the fourth quarter of 2012 versus the fourth quarter of 2011 declined 3 percent driven by a decrease in unit demand from loss of share to biosimilars in Europe. Sales were flat for the full year as price increases offset unit declines. ENBREL sales for the fourth quarter of 2012 versus the fourth quarter of 2011 increased 23 percent driven by increases in the average net sales price and unit demand. Sales increased 14 percent for the full year due mainly to price increases and unit growth. Aranesp® (darbepoetin alfa) sales decreased 9 percent for the fourth quarter of 2012 versus the fourth quarter of 2011 and 11 percent for the full year due to changes in practice patterns.  Sequentially, sales were down 2 percent.  EPOGEN® (epoetin alfa) sales for the fourth quarter of 2012 versus the fourth quarter of 2011 decreased 1 percent driven by a reduction in dose utilization, offset largely by a reduction in customer discounts and favorable changes in accounting estimates. Sales for the full year decreased 5 percent as unit declines were offset partially by a reduction in customer discounts and favorable changes in accounting estimates. Sensipar®/Mimpara® (cinacalcet) sales increased 19 percent for the fourth quarter of 2012 versus the fourth quarter of 2011 and 18 percent for the full year due to unit growth and price increases. Combined sales of Vectibix® (panitumumab) and Nplate® (romiplostim) increased 15 percent for the fourth quarter of 2012 versus the fourth quarter of 2011 and 17 percent for the full year due to unit growth. XGEVA sales increased 7 percent on a sequential basis and 113 percent for the full year due to unit growth. Prolia sales increased 40 percent on a sequential basis and 133 percent for the full year due to unit growth.   Product Sales Detail by Product and Geographic Region$Millions, except percentagesQ4 '12Q4 '11YOY ?USROWTOTALTOTALTOTALNeulasta®/ NEUPOGEN®$1,026$280$1,306$1,319(1%)Neulasta®7752199949980%NEUPOGEN®25161312321(3%)Enbrel®1,086751,16194523%Aranesp®187302489538(9%)EPOGEN®4790479486(1%)Sensipar® / Mimpara®1777925621619%Vectibix®306191875%Nplate®57441018026%XGEVA®1783721513460%Prolia®95591548190%Other 0858521*Total product sales$3,315$1,022$4,337$3,90711%* Change in excess of 100% $Millions, except percentagesFY '12FY '11YOY ?USROWTOTALTOTALTOTALNeulasta®/ NEUPOGEN®$4,214$1,138$5,352$5,2123%Neulasta®3,2078854,0923,9524%NEUPOGEN®1,0072531,2601,2600%Enbrel®3,9672694,2363,70114%Aranesp®7821,2582,0402,303(11%)EPOGEN®1,94101,9412,040(5%)Sensipar® / Mimpara®63931195080818%Vectibix®12223735932211%Nplate®21415436829724%XGEVA®644104748351*Prolia®292180472203*Other 017317358*Total product sales$12,815$3,824$16,639$15,2959%* Change in excess of 100%Operating Expense and Tax Rate Analysis, on an Adjusted BasisCost of Sales, excluding the impact of the Puerto Rico excise tax, increased 0.3 points to 14.7 percent in the fourth quarter of 2012 and increased 0.4 points to 14.4 percent for the full year due to product mix, offset partially by manufacturing efficiencies and higher average net sales price.  Research & Development (R&D) expenses increased 9 percent in the fourth quarter of 2012 driven by later-stage clinical programs, primarily AMG 145 and romosozumab (AMG 785). For the full year, R&D expenses increased 6 percent driven by later-stage clinical programs, primarily AMG 145 and romosozumab (AMG 785), offset partially by reduced expenses associated with marketed product support. Selling, General & Administrative (SG&A) expenses increased 13 percent in the fourth quarter of 2012 driven by higher ENBREL profit share expenses and international expansion.  ENBREL profit share expenses increased 27 percent to $414 million in the fourth quarter.  For the full year, SG&A expenses increased 6 percent, driven primarily by higher ENBREL profit share expenses and international expansion, offset partially by a favorable change to the estimated U.S. healthcare reform federal excise fee. ENBREL profit share expenses increased 16 percent to $1,495 million in 2012.$Millions, except percentagesOn an Adjusted BasisQ4 '12Q4 '11YOY ?FY '12FY '11YOY ?Cost of Sales$727$64313%$2,735$2,34517%% of sales16.8%16.5%0.3 pts16.4%15.3%1.1 pts% of sales (Excluding PR excise tax)14.7%14.4%0.3 pts14.4%14.0%0.4 ptsResearch & Development$917$8429%$3,296$3,1166%% of sales21.1%21.6%(0.5) pts19.8%20.4%(0.6) ptsSelling, General & Administrative$1,351$1,19913%$4,717$4,4346%% of sales31.2%30.7%0.5 pts28.3%29.0%(0.7) ptsTOTAL Operating Expenses$2,995$2,68412%$10,748$9,8959%pts: percentage points  Tax Rate increased by 1.8 points to 16.1 percent in the fourth quarter of 2012 due primarily to the unfavorable tax impact of changes in the jurisdictional mix of income and expenses, as well as the benefit in the fourth quarter of 2011 from the federal R&D tax credit which was not reinstated prior to 2012 year-end. This increase was offset partially by the favorable resolution of certain state tax matters related to prior years. For the full year, the adjusted tax rate increased 1.6 points to 15.9 percent due primarily to the federal R&D tax credit included in 2011 but not in 2012, the unfavorable tax impact of changes in the jurisdictional mix of income and expenses, offset partially by the favorable resolution of certain state tax matters related to prior years.  On an Adjusted BasisQ4 '12Q4 '11YOY ?FY '12FY '11YOY ?Tax Rate16.1%14.3%1.8 pts15.9%14.3%1.6 ptsTax Rate (Excluding PR excise tax credits)20.3%18.1%2.2 pts20.3%19.2%1.1 ptspts: percentage pointsCash Flow and Balance Sheet DiscussionThe Company generated $0.6 billion of free cash flow in the fourth quarter of 2012 versus $1.4 billion in the fourth quarter of 2011. The decrease was driven by a $0.8 billion payment related to a previously disclosed legal settlement. For the full year, free cash flow increased $0.7 billion to $5.2 billion driven by improved collections of receivables, termination of fixed to floating interest rate swap agreements, and higher net income, offset partially by the aforementioned legal settlement payment. During the fourth quarter, Amgen repurchased approximately 14 million shares of common stock at a total cost of $1.2 billion and at an average price of $86.56. This brings the total shares repurchased under its $10 billion authorized stock repurchase program to 146 million at a total cost of $9.7 billion and at an average price of $66.37. The Company previously announced a $2 billion increase in share repurchase authorization by its Board of Directors. Amgen expects that this increase will cover the Company's share repurchase activity into 2014. The Company previously announced that its Board of Directors declared a $0.47 per share dividend for the first quarter of 2013. The dividend will be paid on March 7, 2013, to all stockholders of record as of the close of business on Feb. 13, 2013. This represents a 31 percent increase from that paid in each of the previous four quarters.$Billions, except sharesQ4 '12Q4 '11YOY ?FY '12FY '11YOY ?Operating Cash Flow$0.8$1.6($0.8)$5.9$5.1$0.8Capital Expenditures0.20.20.00.70.60.1Free Cash Flow0.61.4(0.8)5.24.50.7Dividend Paid0.30.20.11.10.50.6Cost of Shares Repurchased1.25.2(4.0)4.78.3(3.6)Adjusted Avg. Diluted Shares (millions)778860(82)786912(126)Cash Balance24.120.63.524.120.63.5Adjusted Debt Outstanding26.521.64.926.521.64.9Stockholders' Equity19.119.00.119.119.00.1Note: Numbers may not add due to rounding2013 GuidanceFor the full year 2013, the Company expects:Total revenues to be in the range of $17.8 billion to $18.2 billion and adjusted EPS to be in the range of $6.85 to $7.15. Adjusted tax rate to be in the range of 14 percent to 15 percent. This reflects the impact of the foreign tax credit associated with the Puerto Rico excise tax. Excluding the Puerto Rico excise tax, Amgen expects the adjusted tax rate for 2013 to be in the range of 17 percent to 18 percent. Capital expenditures to be approximately $700 million.Product and Pipeline Update AMG 145:  The Company recently initiated Phase 3 studies in subjects with high levels of LDL cholesterol. Trebananib (AMG 386):  Enrollment has resumed for the Phase 3 study in recurrent ovarian cancer that was previously suspended due to DOXIL® (doxorubicin HCl liposome injection) supply issues. Aranesp:  The Company announced top-line results of the Phase 3 RED-HF® (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial. deCODE Genetics:  The Company completed the acquisition of deCODE Genetics in December 2012. Non-GAAP Financial MeasuresThe Adjusted non-GAAP (U.S. Generally Accepted Accounting Principles) financial measures included above for the three and twelve months ended Dec. 31, 2012 and 2011 exclude, for the applicable periods, certain expenses related to acquisitions, cost-savings initiatives, various legal proceedings, non-cash interest expense associated with our convertible notes and certain other adjustments, as applicable. These adjustments and other items are presented on the attached reconciliations.Management has presented its operating results in accordance with GAAP and on an "adjusted" (or non-GAAP) basis and Free Cash Flow which is a non-GAAP financial measure for the three and twelve months ended Dec. 31, 2012 and 2011. In addition, management has presented its outstanding debt in accordance with GAAP and on an "adjusted" (or non-GAAP) basis as of Dec. 31, 2012 and 2011. The Company believes that the presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses these non-GAAP financial measures in connection with its own budgeting and financial planning.  These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in conformity with GAAP. About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen. Forward-Looking StatementsThis news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2011, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.  No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.  Amgen Inc.Condensed Consolidated Statements of Income - GAAP(In millions, except per share data)(Unaudited)Three months endedYears endedDecember 31, December 31, 2012201120122011Revenues:Product sales$  4,337$       3,907$ 16,639$ 15,295Other revenues8466626287Total revenues4,4213,97317,26515,582Operating expenses:Cost of sales (excludes amortization of certainacquired intangible assets presented below)8526562,9182,427Research and development9388513,3803,167Selling, general and administrative1,3701,2084,8014,486Amortization of certain acquired intangible assets7373294294Other10023295896Total operating expenses3,3332,81111,68811,270Operating income1,0881,1625,5774,312Interest expense, net2911951,053610Interest and other income, net12684485448Income before income taxes9231,0515,0094,150Provision for income taxes135117664467Net income$     788$          934$   4,345$   3,683Earnings per share:Basic$    1.03$         1.09$     5.61$     4.07Diluted$    1.01$         1.08$     5.52$     4.04Average shares used in calculationof earnings per share:Basic763854775905Diluted778861787912 Amgen Inc.Condensed Consolidated Balance Sheets - GAAP (In millions)(Unaudited)December 31, December 31, 20122011AssetsCurrent assets:Cash, cash equivalents and marketable securities$                 24,061$                 20,641Trade receivables, net2,5182,896Inventories2,7442,484Other current assets1,8861,572Total current assets31,20927,593Property, plant and equipment, net5,3265,420Intangible assets, net3,9682,584Goodwill12,66211,750Other assets1,1331,524Total assets$                 54,298$                 48,871Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable and accrued liabilities$                   5,608$                   5,670Current portion of long-term debt2,49584Total current liabilities8,1035,754Long-term debt24,03421,344Other non-current liabilities3,1012,744Stockholders' equity19,06019,029Total liabilities and stockholders' equity$                 54,298$                 48,871Shares outstanding756796Amgen Inc.GAAP to "Adjusted" Reconciliations(In millions)(Unaudited)Three months endedYears endedDecember 31, December 31, 2012201120122011GAAP cost of sales$    852$          656$   2,918$        2,427Adjustments to cost of sales:Certain charges pursuant to our continuing efforts to improve cost efficiencies in our operations (a)(118)(11)(160)(65)Acquisition-related expenses(4)-(11)(7)Stock option expense (b)(3)(2)(12)(10)Total adjustments to cost of sales(125)(13)(183)(82)Adjusted cost of sales$    727$          643$   2,735$        2,345GAAP research and development expenses$    938$          851$   3,380$        3,167Adjustments to research and development expenses:Acquisition-related expenses(16)(1)(50)(28)Certain charges pursuant to our continuing efforts to improve cost efficiencies in our operations--(12)-Reversal of previously accrued expenses for bonuses and stock-based compensation awards, which were forfeited as a result of the employees' termination pursuant to our continuing efforts to improve cost efficiencies in our operations---12Stock option expense  (b)(5)(8)(22)(35)Total adjustments to research and development expenses(21)(9)(84)(51)Adjusted research and development expenses$    917$          842$   3,296$        3,116GAAP selling, general and administrative expenses$  1,370$        1,208$   4,801$        4,486Adjustments to selling, general and administrative expenses:Acquisition-related expenses(14)(1)(59)(12)Stock option expense (b)(5)(8)(25)(40)Total adjustments to selling, general and administrative expenses(19)(9)(84)(52)Adjusted selling, general and administrative expenses$  1,351$        1,199$   4,717$        4,434GAAP operating expenses$  3,333$        2,811$  11,688$      11,270Adjustments to operating expenses:Adjustments to cost of sales(125)(13)(183)(82)Adjustments to research and development expenses(21)(9)(84)(51)Adjustments to selling, general and administrative expenses(19)(9)(84)(52)Non-cash amortization of product technology rights acquired in a prior year business combination(73)(73)(294)(294)Certain charges pursuant to our continuing efforts to improve cost efficiencies in our operations(69)(30)(175)(109)Acquisition-related expenses(6)-(25)-(Expense)/benefit resulting from changes in the estimated fair values of the contingent consideration obligations related to a prior year business combination(26)8(31)(1)Benefit/(expenses) related to various legal proceedings1(1)(64)(786)Total adjustments to operating expenses(338)(127)(940)(1,375)Adjusted operating expenses$  2,995$        2,684$  10,748$        9,895GAAP operating income$  1,088$        1,162$   5,577$        4,312Adjustments to operating expenses3381279401,375Adjusted operating income$  1,426$        1,289$   6,517$        5,687GAAP income before income taxes$    923$        1,051$   5,009$        4,150Adjustments to income before income taxes:Adjustments to operating expenses3381279401,375Non-cash interest expense associated with our convertible notes3634140143Total adjustments to income before income taxes3741611,0801,518Adjusted income before income taxes$  1,297$        1,212$   6,089$        5,668GAAP provision for income taxes$    135$          117$      664$          467Adjustments to provision for income taxes:Income tax effect of the above adjustments (c)9756329331Income tax net expense/(benefit) related to certain prior period items excluded from "Adjusted" earnings(23)-(23)12Total adjustments to provision for income taxes7456306343Adjusted provision for income taxes$    209$          173$      970$          810GAAP net income$    788$          934$   4,345$        3,683Adjustments to income before income taxes, net of the tax effect of the above adjustments2771057511,187Income tax net expense/(benefit) related to certain prior period items excluded from "Adjusted" earnings23-23(12)Adjusted net income$  1,088$        1,039$   5,119$        4,858Amgen Inc.GAAP to "Adjusted" Reconciliations(In millions, except per share data)(Unaudited)The following table presents the computations for GAAP and "Adjusted" diluted EPS, computed under the treasury stock method."Adjusted" EPS presented below excludes stock option expense:Three months endedThree months endedDecember 31, 2012December 31, 2011GAAP"Adjusted"  GAAP"Adjusted"  Income (Numerator):Net income for basic and diluted EPS$    788$        1,088$      934$        1,039Shares (Denominator):Weighted-average shares for basic EPS763763854854Effect of dilutive securities1515(*)76(*)Weighted-average shares for diluted EPS778778861860Diluted EPS$   1.01$         1.40$     1.08$         1.21Year endedYear endedDecember 31, 2012December 31, 2011GAAP"Adjusted" GAAP"Adjusted" Income (Numerator):Net income for basic and diluted EPS$  4,345$        5,119$   3,683$        4,858Shares (Denominator):Weighted-average shares for basic EPS775775905905Effect of dilutive securities1211(*)77(*)Weighted-average shares for diluted EPS787786912912Diluted earnings per share$   5.52$         6.51$     4.04$         5.33(*)  Dilutive securities used to compute "Adjusted" diluted EPS for the three months and years ended December 31, 2012 and 2011 were computed under the treasury stock method assuming that we do not expense stock options.(a)The adjustments during the years ended 2012 and 2011 include incremental expenses resulting from our transaction with Boehringer Ingelheim.  The adjustment during the three months ended December 31, 2012, relates to a charge in connection with the rationalization of our worldwide manufacturing operations.(b)For the three months and years ended December 31, 2012 and 2011, the total pre-tax expense for employee stock options was $13 million and $59 million, respectively and $18 million and $85 million, respectively."Adjusted" diluted EPS including the impact of stock option expense for the three months and years ended December 31, 2012 and 2011 was as follows: Three months endedYears endedDecember 31, December 31, 2012201120122011"Adjusted" diluted EPS, excluding stock option expense$   1.40$         1.21$     6.51$         5.33Impact of stock option expense (net of tax)(0.01)(0.02)(0.06)(0.07)"Adjusted" diluted EPS, including stock option expense$   1.39$         1.19$     6.45$         5.26(c)The tax effect of the adjustments between our GAAP and "Adjusted" results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s).  Generally, this results in a tax impact at the U.S. marginal tax rate for certain adjustments, including amortization of intangible assets and non-cash interest expense associated with our convertible notes, whereas the tax impact of other adjustments, including stock option expense, depends on whether the amounts are deductible in the tax jurisdictions where the expenses are incurred or the asset is located and the applicable tax rate(s) in those jurisdictions. Due to these factors, the effective tax rates for the adjustments to our GAAP income before income taxes, for the three months and years ended December 31, 2012, were 25.9% and 30.5%, respectively, compared with 34.8% and 21.8% for the corresponding periods of the prior year.Amgen Inc.Reconciliation of GAAP Debt Outstanding to "Adjusted" Debt Outstanding(In millions)(Unaudited)GAAPAdjustments for accounting standard (a)"Adjusted"December 31, 2011$           21,428$                  154$           21,582December 31, 2012$           26,529$                    12$           26,541(a)To exclude the impact of bifurcating the debt and equity components of our convertible notes as required by U.S. accounting standards for these securities commencing in 2009. Reconciliation of Free Cash Flow(In millions)(Unaudited)Three months endedYears endedDecember 31, December 31,2012201120122011Cash Flows from Operations$                       812$                  1,584$              5,882$              5,119Capital Expenditures(200)(224)(689)(567)Free Cash Flow$                       612$                  1,360$              5,193$              4,552Amgen Inc.Reconciliation of GAAP EPS Guidance to "Adjusted" EPS Guidance for the Year Ending December 31, 2013(Unaudited)2013GAAP EPS (diluted) guidance$        6.46-$        6.76Known adjustments to arrive at "Adjusted" earnings*:Amortization of acquired intangible assets(a)0.34Stock option expense(b)0.04Non-cash interest expense associated with our convertible notes(c)0.01"Adjusted" EPS (diluted) guidance$        6.85-$        7.15*The known adjustments are presented net of their related aggregate tax impact of approximately $0.19 per share. (a)To exclude the non-cash amortization of intangible assets acquired in prior year business combinations.(b)To exclude stock option expense.(c)To exclude the non-cash interest expense associated with our convertible notes.Reconciliation of GAAP Tax Rate Guidance to "Adjusted" Tax Rate Guidance for the Year Ending December 31, 2013(Unaudited)2013 with PR excise tax credit2013 without PR excise tax creditGAAP tax rate guidance12.5%-13.6%15.8%-16.9%Tax rate effect of known adjustments discussed above1.5%-1.4%1.2%-1.1%"Adjusted" tax rate guidance14.0%-15.0%17.0%-18.0%  CONTACT: Amgen, Thousand OaksAshleigh Koss, 805-313-6151 (media)Arvind Sood, 805-447-1060 (investors)(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)SOURCE Amgen